Fragmento

Dear Editor: Chronic hepatitis C virus (HCV) infection is the lead-ing reason for liver transplantation in Western countries.¹ Unfortunately, reinfection of the graft is universal aftertransplantation,² occurring early at reperfusion.³ There is no accepted approach for preventing reinfection, but strategies aimed at blocking viral entry to the hepatocyte seem interesting in this clinical scenario. HCV circulates in human serum associated with various lipoproteins, including HDL, LDL and VLDL, forming lipoviral particles(LVP),^4-6 and among the various entry factors described, several are related to lipoprotein receptors, including LDL receptor⁷ and scavenger receptor class B type I(SCARB1, also known as SR-BI).⁸ In 2012 a new entry factor was described: Niemann-Pick C1-like 1 (NPC1L1).⁹ NPC1L1 is a cholesterol-sensing receptor expressed in enterocytes and in the liver in humans, which can be antagonized by ezetimibe.

Palabras clave:

2016-10-21   |   254 visitas   |   Evalua este artículo 0 valoraciones

Vol. 15 Núm.5. Septiembre-Octubre 2016 Pags. 803-805 Ann Hepatol 2016; 15(5)